CHERRY HILL, N.J.--(BUSINESS WIRE)--Sept. 8, 2004--Infotonics Technology Center and Medi-photonics Development Company LLC, a subsidiary of Cherry Hill New Jersey-based Mediscience Technology Corp. (MTC), (OTCBB:MDSC), a developer of proprietary non-invasive imaging technology for molecular detection of cancer and physiological change, announced their intent to agree to jointly develop the "Compact Photonic Explorer" (CPE), or "pill camera," for medical and non-medical applications. The parties initial focus of the project is developing a (CPE) that would detect cancer and monitor body functions.

The proof-of-concept research for the (CPE), led by Dr. Robert Alfano and his team at City University of New York (CUNY), has been successful based upon an on-going four-year multidisciplinary/multi-institutional effort to develop miniature devices that use light to remotely monitor the health of various environments in collaboration with researchers at Cornell, SUNY Albany, SUNY Binghamton, RPI, Rochester Institute of Technology, the University of Rochester, and Boston University.

Infotonics Technology Center Inc. (Infotonics) is a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation, a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems.

Mediscience President Michael Engelhart stated, "the first goal of a joint development initiative would be to create an ingestible photonic pill that would enable physicians to detect early stage cancer of the complete auto-digestive tract. Such a non-invasive device would lead to reduced mortality and health care costs, and would significantly increase the number of people who could be screened for this type of cancer; further an agreement between Medi-photonics and Infotonics would be a synergistic and strategic fit leveraging the Center's unique nanotechnology capabilities and resources to provide our customers and partners with an exceptional state of the art competitive advantage."

Mediscience Chairman Peter Katevatis Esq. stated, "This project has and will continue to enhance Mediscience proprietary non-invasive imaging technology for molecular detection of cancer and physiological change and the Company's desire to move forward to commercialize its patented Optical Biopsy technology as it also prepares and initiates clinical trials for cervical cancer applications."

Les Fritzemeier, Infotonics' Director of Business Development and Government Programs, said such an agreement will be "a milestone" for the Center, since the (CPE) stems from collaborative, Infotonics-funded research at eight universities over the past two years. "This is a prime example of the role the Infotonics Center can play in moving innovations into the marketplace to drive economic growth."

Engelhart and Fritzemeier noted that medical applications for a photonic pill device would be just a starting point. Non-medical applications could involve sensing biological and chemical species, such as bacteria and pollutants, or for surveillance to determine the safety of compact structures and devices.

About the Infotonics Center

The Infotonics Technology Center Inc. (Infotonics) is a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems. Infotonics is structured as a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation. The Rochester Regional Photonics Cluster is an industrial partner, and academic participants include some 20 New York State colleges and universities. Infotonics' goal is to establish a unique, world-class research and development facility to enable rapid commercialization of new products. This initiative will provide major benefits to the region, including creation of jobs and attraction of new companies and investment revenue.

About Mediscience Technology

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

See Web sites:

www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp

www.cunyphotonics.com

www.MEDISCIENCETECH.com

See Mediscience 8-K filing dated September 8 , 2004

See New England Journal of Medicine 7-29-04 (general results of
developing capsule endoscopic technology)